Table 1 The baseline characteristics of all eligible trials in this meta-analysis
From: The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis
Author (year) | Ethnicity | Status | PWV type | Design | Masking | ARB type | Drugs in controls | Treatment | Control | Follow-up (months) |
---|---|---|---|---|---|---|---|---|---|---|
Mahmud and Feely8 | Caucasian | Hypertension | cfPWV | Crossover | Open | Valsartan | ACEI | 12 | 12 | 4 |
Mahmud and Feely8 | Caucasian | Hypertension | cfPWV | Crossover | Double | Losartan | Diuretics | 11 | 11 | 4 |
Asmar et al.26 | Caucasian | Hypertension | cfPWV | Crossover | Double | Telmisartan | Placebo | 20 | 20 | 3 |
Suzuki et al.36 | East Asian | Others | baPWV | Parallel | Double | Valsartan | Placebo | 14 | 10 | 48 |
Takami and Shigemasa37 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 20 | 16 | 12 |
Takami and Shigemasa37 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 20 | 20 | 12 |
Takami and Shigemasa37 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | ACEI | 20 | 20 | 12 |
Munakata et al.32 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 21 | 20 | 12 |
Anan25 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | ACEI | 10 | 11 | 40 |
Ichihara et al.27 | East Asian | Hypertension | baPWV | Parallel | Open | Losartan | ACEI | 22 | 21 | 48 |
Ichihara et al.27 | East Asian | Hypertension | baPWV | Parallel | Open | Losartan | Placebo | 22 | 21 | 48 |
Ichihara et al.28 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 50 | 50 | 48 |
Rajagopalan et al.34 | Caucasian | Healthy | cfPWV | Crossover | Double | Valsartan | Placebo | 33 | 33 | 13 |
Morimoto et al.31 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 21 | 22 | 24 |
Zhao50 | East Asian | Hypertension | cfPWV | Parallel | NA | Valsartan | Placebo | 20 | 20 | 12 |
Rehman et al.35 | Caucasian | Hypertension | cfPWV | Parallel | Double | Losartan | ACEI | 19 | 20 | 12 |
Nakayama et al.33 | East Asian | Hypertension | baPWV | Parallel | Double | Telmisartan | Beraprost sodium | 20 | 20 | 12 |
Kosch et al.29 | Caucasian | Hypertension | cfPWV | Parallel | Double | Valsartan | Beta blocker | 25 | 27 | 12 |
Zheng and Lin51 | East Asian | Hypertension | baPWV | Parallel | Open | Valsartan | Diuretics | 21 | 18 | 12 |
Zheng and Lin51 | East Asian | Hypertension | baPWV | Parallel | Open | Valsartan | Beta blocker | 21 | 20 | 12 |
Zheng and Lin51 | East Asian | Hypertension | baPWV | Parallel | Open | Valsartan | CCB | 21 | 24 | 12 |
Zheng and Lin51 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | ACEI | 21 | 22 | 12 |
Nakamura et al.12 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 15 | 15 | 48 |
Ishii et al.17 | East Asian | Hypertension | baPWV | Parallel | Open | Candesartan | CCB | 11 | 11 | 12 |
Shigenaga et al.22 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | Non-RAS | 15 | 15 | 24 |
Shigenaga et al.22 | East Asian | Hypertension | baPWV | Parallel | NA | Candesartan | Non-RAS | 15 | 15 | 24 |
Ruan et al.46 | East Asian | heart failure | baPWV | Parallel | Open | Irbesartan | Non-RAS | 25 | 22 | 12 |
Li et al.43 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | ACEI | 34 | 34 | 12 |
Li et al.43 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 34 | 34 | 12 |
Mitsuhashi et al.11 | East Asian | Hypertension | baPWV | Parallel | Open | Losartan | Non-RAS | 20 | 20 | 48 |
Long and Liu45 | East Asian | Others | baPWV | Parallel | NA | Valsartan | CCB | 35 | 40 | 24 |
Li and Wang44 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 48 | 45 | 12 |
Li and Wang44 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | Diuretics | 48 | 42 | 12 |
Ruan et al.47 | East Asian | Hypertension | baPWV | Parallel | Open | Candesartan | Non-RAS | 23 | 19 | 12 |
Han et al.19 | East Asian | Others | baPWV | Parallel | Open | Valsartan | Statins | 57 | 57 | 24 |
Lunder et al.21 | Caucasian | Healthy | cfPWV | Parallel | Double | Valsartan | Placebo | 20 | 20 | 4 |
Wu et al.48 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 48 | 50 | 2 |
Wu et al.48 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | ACEI | 48 | 49 | 2 |
He et al.39 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | CCB | 44 | 44 | 12 |
Feng38 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 44 | 49 | 12 |
Tomiyama et al.20 | East Asian | Hypertension | baPWV | Parallel | Open | Candesartan | CCB | 56 | 57 | 32 |
Hayoz et al.10 | Caucasian | Hypertension | baPWV | Parallel | Double | Valsartan | CCB | 63 | 62 | 38 |
Spanos et al.13 | Caucasian | Hypertension | cfPWV | Parallel | NA | Valsartan | Renin inhibitor | 14 | 15 | 24 |
Yang et al.49 | East Asian | Hypertension | baPWV | Parallel | NA | Valsartan | Diuretics | 42 | 40 | 24 |
Kong et al.41 | East Asian | Hypertension | baPWV | Parallel | Open | Irbesartan | ACEI | 34 | 34 | 12 |
Kong et al.41 | East Asian | Hypertension | baPWV | Parallel | Open | Irbesartan | CCB | 34 | 34 | 12 |
Li and Ma42 | East Asian | Hypertension | baPWV | Parallel | Open | Telmisartan | CCB | 33 | 34 | 24 |
Huang et al.40 | East Asian | Hypertension | baPWV | Parallel | Double | Losartan | Eplerenone | 40 | 37 | 12 |
Kim et al.11 | East Asian | Hypertension | cfPWV | Parallel | Open | Losartan | Beta blocker | 88 | 94 | 24 |
Ihm et al.24 | East Asian | Hypertension | cfPWV | Parallel | Open | Losartan | CCB | 99 | 101 | 24 |
Agnoletti et al.23 | Caucasian | Hypertension | cfPWV | Parallel | Open | Candesartan | CCB | 33 | 33 | 12 |
Agnoletti et al.23 | Caucasian | Hypertension | cfPWV | Parallel | Open | Candesartan | Diuretics | 33 | 44 | 12 |
Agnoletti et al.23 | Caucasian | Hypertension | cfPWV | Parallel | Open | Candesartan | Placebo | 33 | 35 | 12 |